ArticleCancer2022
Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor.
Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Guideline
- Article
- Examining HPV vaccination coverage among childhood, adolescent, and young adult cancer survivors: a report from the St. Jude Lifetime Cohort study.Journal of cancer survivorship : research and practice · 2026Article
- Secondary Neoplasm in Survivors of Childhood Hematological Malignancies-Systematic Review.Children (Basel, Switzerland) · 2026Review
- Human papillomavirus vaccination among childhood cancer survivors: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Implementation barriers and considerations for recommending and administering the human papillomavirus (HPV) vaccination in oncology settings.Journal of cancer survivorship : research and practice · 2024Article
- Article
- Review
- Nomograms constructed for predicting diagnosis and prognosis in cervical cancer patients with second primary malignancies: a SEER database analysis.Journal of cancer research and clinical oncology · 2023Article
- Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination.Frontiers in immunology · 2023Article
- Subsequent Primary Cancer Risk Among 5-Year Survivors of Adolescent and Young Adult Cancers.Journal of the National Cancer Institute · 2022Article
- Human papillomavirus (HPV) vaccination is cancer prevention for childhood cancer survivors.Cancer · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV)-associated subsequent malignant neoplasms (SMN
methodsThe cumulative risk of SMN
resultsIn total, 46 survivors developed an SMN
conclusionsChildhood cancer survivors are at increased risk for SMN in sites susceptible to HPV-associated malignancies. Further research examining HPV in the etiology of SMN and the promotion of HPV vaccination and surveillance guidelines for SMN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.